Methoxyamine
Pronunciation: meh-THOK-see-uh-meen.
- Generic name
- Methoxyamine
- Brand names
- Methoxytreat, Methoxyamine, Oxyamin
- Drug class
- DNA Repair Inhibitor; Antineoplastic Agent
Availability and supply rules vary by country
Trade names by country:
Australia: · Full directory
What Methoxyamine is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how Methoxyamine works
Methoxyamine acts as a DNA repair inhibitor by binding to apurinic/apyrimidinic (AP) sites in DNA, preventing the base excision repair (BER) pathway from correcting DNA damage. This leads to accumulation of DNA lesions in cancer cells, enhancing the cytotoxic effects of alkylating chemotherapy agents and promoting cancer cell death. (2)
What Methoxyamine is used for
Potentiation of chemotherapy in cancer treatment
Potentiation of chemotherapy in cancer treatment (2)
Radiosensitizer in cancer therapy
Radiosensitizer in cancer therapy (2)
Research tool for studying DNA repair mechanisms
Research tool for studying DNA repair mechanisms (2)
Before taking Methoxyamine
Do not take / not appropriate for
- Contraindicated in patients with hypersensitivity to methoxyamine, severe hepatic or renal impairment, and during pregnancy or breastfeeding. (Contraindication) (2)
Tell your clinician about
(2)How to take Methoxyamine
- General Instructions: Methoxyamine is administered by a healthcare professional, usually as an intravenous infusion. Follow your doctor's instructions closely and attend all scheduled appointments.. Adult Dosing: Typical dosing is individualized based on body surface area and the specific chemotherapy regimen. Refer to your oncologist's protocol.. Pediatric Dosing: Safety and efficacy in children have not been established. Use in pediatric patients is not routinely recommended unless under specialist supervision.. Administration: Given as an intravenous infusion over a specified period, often in combination with other chemotherapy agents.. When To Stop: Treatment may be discontinued if severe side effects occur, if there is evidence of disease progression, or as directed by your oncologist.. Storage: Methoxyamine vials should be stored according to manufacturer instructions, typically in a refrigerator (2–8°C) and protected from light. Do not freeze.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (2)
Missed dose
If you miss a scheduled dose, contact your healthcare provider immediately to reschedule. Do not attempt to self-administer or double up on doses.
Overdose
In case of suspected overdose, seek emergency medical attention. Symptoms may include severe nausea, vomiting, neurological changes, or profound bone marrow suppression. Supportive care and monitoring are essential. (2)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Myelosuppression
Incidence: Reported in the clinician-authored database; frequency not established
Nausea
Incidence: Reported in the clinician-authored database; frequency not established
Vomiting
Incidence: Reported in the clinician-authored database; frequency not established
Fatigue
Incidence: Reported in the clinician-authored database; frequency not established
Anemia
Incidence: Reported in the clinician-authored database; frequency not established
Thrombocytopenia
Incidence: Reported in the clinician-authored database; frequency not established
Leukopenia
Incidence: Reported in the clinician-authored database; frequency not established
Serious warnings
May cause severe bone marrow suppression — serious
Symptoms: May cause severe bone marrow suppression. Risk of serious allergic reactions. Potential for liver and kidney toxicity. Use with caution in elderly patients. Not recommended during pregnancy or breastfeeding.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindicated in patients with hypersensitivity to methoxyamine, severe hepatic or renal impairment, and during pregnancy or breastfeeding. Use with caution in elderly patients and those with pre-existing bone marrow suppression. Monitor closely in patients with hepatic or renal dysfunction.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | Methoxyamine may interact with other chemotherapy agents, immunosuppressants, and drugs affecting liver enzymes. Inform your healthcare provider of all medications and supplements you are taking. Avoid combining with drugs that are nephrotoxic or hepatotoxic unless closely monitored. | (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
The clinician-authored record contraindicates methoxyamine during pregnancy. This is corroborated by published early-phase (Phase I) clinical-trial protocols for methoxyamine (TRC102), which excluded pregnant individuals from enrollment; no human pregnancy safety data exist. Methoxyamine (like the chemotherapy it is combined with) should not be used in pregnancy, and effective contraception should be discussed with the treating oncology team. (2)
Breastfeeding
The clinician-authored record contraindicates methoxyamine during breastfeeding. This is corroborated by published early-phase clinical-trial protocols for methoxyamine (TRC102), which excluded breastfeeding individuals from enrollment; it is not known whether methoxyamine passes into breast milk. Discuss feeding options with the treating oncology team before starting treatment. (2)
Children
Frequency: Not recommended for pediatric use. Weight Based: Not recommended for pediatric use. Max Daily Dose: Not recommended for pediatric use. Max Single Dose: Not recommended for pediatric use. Age Restrictions: Safety not established in children (2)
Renal_impairment
The clinician-authored record states methoxyamine is contraindicated in patients with severe hepatic or renal impairment, and that patients with hepatic or renal dysfunction should be monitored closely. This is consistent with published early-phase (Phase I) methoxyamine (TRC102) trial protocols, which required adequate baseline liver, kidney, and marrow function for enrollment (e.g., creatinine less than 1.5x the upper limit of normal; total bilirubin no more than 1.5x, and AST/ALT no more than 2.5x, the upper limit of normal). No specific numeric dose-reduction schedule for lesser degrees of renal or hepatic impairment has been established; any use in a patient with organ impairment should be individually assessed by the treating oncology team. (2)
Hepatic_impairment
The clinician-authored record states methoxyamine is contraindicated in patients with severe hepatic or renal impairment, and that patients with hepatic or renal dysfunction should be monitored closely. This is consistent with published early-phase (Phase I) methoxyamine (TRC102) trial protocols, which required adequate baseline liver, kidney, and marrow function for enrollment (e.g., creatinine less than 1.5x the upper limit of normal; total bilirubin no more than 1.5x, and AST/ALT no more than 2.5x, the upper limit of normal). No specific numeric dose-reduction schedule for lesser degrees of renal or hepatic impairment has been established; any use in a patient with organ impairment should be individually assessed by the treating oncology team. (2)
Monitoring
(2)Storage
Methoxyamine vials should be stored according to manufacturer/pharmacy instructions, typically refrigerated (2-8°C / 36-46°F) and protected from light. Do not freeze.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: Potentiation of chemotherapy in cancer treatment
Dose summary: Not established
Renal context: The clinician-authored record contraindicates methoxyamine in severe renal impairment and calls for close monitoring in renal dysfunction. Published early-phase (Phase I) methoxyamine (TRC102) trial protocols required adequate baseline renal function (creatinine less than 1.5x the upper limit of normal) for enrollment. No specific numeric renal dose-reduction schedule has been established outside a clinical-trial protocol. (2)
Hepatic guidance
The clinician-authored record contraindicates methoxyamine in severe hepatic impairment and calls for close monitoring in hepatic dysfunction. Published early-phase (Phase I) methoxyamine (TRC102) trial protocols required adequate baseline hepatic function (total bilirubin no more than 1.5x, and AST/ALT no more than 2.5x, the upper limit of normal) for enrollment. No specific numeric hepatic dose-reduction schedule has been established outside a clinical-trial protocol.
Frequently asked questions
What is methoxyamine used for?
Methoxyamine is used in combination with chemotherapy to treat certain cancers by making cancer cells more sensitive to treatment.
How is methoxyamine given?
It is administered as an intravenous infusion by a healthcare professional, usually in a hospital or clinic.
What are the most common side effects?
Common side effects include nausea, vomiting, fatigue, headache, and mild changes in blood counts.
Can I take methoxyamine if I am pregnant?
Methoxyamine is not recommended during pregnancy due to potential risks to the fetus. Discuss family planning with your doctor before starting treatment.
What should I do if I miss a dose?
Contact your healthcare provider immediately to reschedule. Do not attempt to self-administer or double up on doses.
Are there any foods or drugs I should avoid?
Avoid alcohol, live vaccines, and any new medications or supplements without consulting your doctor.
How will my doctor monitor my treatment?
Your doctor will monitor your blood counts, liver and kidney function, and watch for side effects throughout your treatment.
What happens if I take too much Methoxyamine?
Taking too much Methoxyamine can lead to severe adverse effects, potentially exacerbating its intended actions and causing systemic toxicity. Symptoms of overdose may include increased side effects or new, serious complications. If you suspect an overdose, seek immediate emergency medical attention. Do not attempt to self-treat or wait for symptoms to worsen.
Can I drink alcohol while taking Methoxyamine?
It is generally advisable to avoid or limit alcohol consumption while taking Methoxyamine. As a DNA Repair Inhibitor and Antineoplastic Agent, Methoxyamine can have significant effects on the body, and alcohol may interact with the medication, potentially increasing side effects, impairing liver function, or reducing the drug's effectiveness. Always consult your healthcare provider for personalized advice regarding alcohol use.
Is Methoxyamine safe during pregnancy?
The safety of Methoxyamine during pregnancy is a significant concern. It is categorized as 'Consult doctor' regarding pregnancy. This means that the potential risks to the fetus are not fully established or are considered high, and its use requires careful evaluation by a healthcare provider. Pregnant individuals or those planning pregnancy should discuss the risks and benefits thoroughly with their doctor before using Methoxyamine.
What is the mechanism of action of Methoxyamine?
Methoxyamine acts as a DNA repair inhibitor by binding to apurinic/apyrimidinic (AP) sites in DNA, preventing the base excision repair (BER) pathway from correcting DNA damage. This leads to accumulation of DNA lesions in cancer cells, enhancing the cytotoxic effects of alkylating chemotherapy agents and promoting cancer cell death. (2)
What is the generic name of Methoxyamine?
The generic name is Methoxyamine. It is sold under brand names including Methoxytreat, Methoxyamine, Oxyamin.
What class of drug is Methoxyamine?
Methoxyamine is classed as: DNA Repair Inhibitor; Antineoplastic Agent.
References
- Clinician-authored medicine record for Methoxyamine (MedGuideGlobal medicines database)MedGuideGlobal clinician-authored medicine record · null · accessed 2026-08-06 · source 1
- Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomasPMC (NCBI) — peer-reviewed published Phase I clinical trial report · United States · accessed 2026-08-07 · source 2
Brand names by country
Single-ingredient Methoxyamine names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.